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ABSTRACT 
During the drug design process, there are many different approaches that 
researchers can take to improve the overall efficacy of a potential drug candidate. Aside 
from attempting to understand how different functional groups interact with target 
tissues, the physical properties of a particular molecule are also important determinants of 
overall effectiveness. If a molecule is too polar, it will display low permeability through 
the gastrointestinal tract, and will most likely be excreted through the body unchanged. 
Conversely, if a molecule is too nonpolar, it will be insoluble in blood and will display 
low distribution throughout tissues. This research describes attempts at the synthesis of 
multiple ferrocene-oxadiazole complexes, with an effort towards synthesizing 
compounds which display an aqueous solubility similar to candidates currently used in 
drug design. Oxadiazoles are a class of 5-membered, heterocyclic molecules which have 
attracted a tremendous amount of attention in recent years for their vast array of 
medicinal properties. Furthermore, the conjugation of ferrocene to bioactive molecules 
has demonstrated involvement with the suppression of cancer cells in mice. In this 
project, the aqueous solubility of one such ferrocene-oxadiazole complex was estimated 
using the LogD shake-flask assay, resulting in a value of 1.21. The results of an 
attempted synthesis of a more hydrophobic ferrocene-oxadiazole complex will be 
explained as well, along with a discussion of the challenges associated with different 
synthetic methods. 
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1. INTRODUCTION 
This research is focused on attempts at synthesizing ferrocene molecules 
derivatized with an oxadiazole-containing sidechain. The method of preparation of the 
oxadiazole will be through a reaction of a ferrocene derivative with mercury (II) acetate, 
which has been shown to produce a ferrocene with a 1,3,4 oxadiazole-containing 
sidechain as the final product through a general mechanism similar to Scheme 1.1 
 
Scheme 1. Oxadiazole Synthesis1 
 
When the same reaction with Hg2+ occurs with different reactant structures, it is unknown 
whether or not cyclization of the final product will occur due to the selectivity of the 
reaction between the thiophilic mercury (II) ion and the thiosemicarbazide sidechain. 
Since there is a large amount of recent research discussing the potential medicinal 
applications of oxadiazole-containing drugs, including areas such as anticancer, anti-
inflammatory, anti-microbial, and anti-viral medications, the goal of this research is to be 
able to synthesize a new compound which displays similar aqueous solubility and other 
physical properties to drug molecules currently used in a clinical setting.2 A discussion of 
oxadiazoles, their properties and applications, as well as a basic overview of the 
principles which are involved in drug development will be given, as well as a brief 
experimental description. 
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1.1 Medicinal Properties of Oxadiazoles 
Some of the most interesting compounds currently under investigation by 
medicinal chemists and pharmacologists are a group of heterocyclic molecules called 
oxadiazoles. Oxadiazoles consist of two carbon atoms, two nitrogen atoms, and an 
oxygen atom arranged in a five-membered ring, with double bonds connecting the carbon 
and nitrogen atoms. In their most stable form, oxadiazoles can exist as either the 1,2,4 
(Figure 1) or the 1,3,4 (Figure 2) isomer. The isomers exhibit a significant variation in 
their physical and thermodynamic properties, both of which in turn affect their potential 
pharmaceutical uses3.  
      
             Figure 1. 1,2,4 oxadiazole                                                           Figure 2. 1,3,4 oxadiazole 
1,2,4 oxadiazoles are commonly synthesized from nitriles or a similar amidoxime 
derivative4, while 1,3,4 oxadiazoles with various substitution patterns can be obtained 
from a reaction of acylhydrazides with acylating agents, or by dehydration of an 
acylsemicarbazide.5  
 
Scheme 2. 1,3,4 oxadiazole preparation via reaction of acylhydrazide with cyanogen bromide (i) and dehydration of acylsemicarbazide (ii).5   
3  
  
 Scheme 3. 1,2,4 oxadiazole preparation from carboxylic esters and amidoximines.4    
The differences in the structure of the 1,2,4- and the 1,3,4- isomers contribute 
heavily to a strong variation in physical properties. 1,3,4-oxadiazoles typically display 
much lower lipophilicity than the 1,2,4- isomers and a higher aqueous solubility, which 
can be attributed to the more pronounced dipole vector among the 1,3,4-oxadiazoles 
compared with the 1,2,4-oxadiazoles, as shown in Figure 3. Metabolic stability, which is 
a quantitative measure of the percentage of a compound degraded over time in the 
presence of a metabolically active system (such as the human body), was also shown to 
be greater in the 1,3,4- isomer verses the 1,2,4- isomer. Similar differences in activity are 
also demonstrated in the inhibition of cytochrome 450 enzymes, which are a class of 
enzymes involved in human liver microsome (HLM) metabolism. The 1,3,4- oxadiazoles 
display a much higher resiliency against HLM metabolism compared with that of the 
1,2,4-oxadiazoles. In addition, the decreased inhibition of the hERG ion channel, which 
correlates to a decrease in lipophilicity, is also observed in the 1,3,4 oxadiazole 
compound. The differences in the physical properties of each isomer can be rationalized 
by the difference in charge distributions.3 
4  
                         
Figure 3. Charge distributions and dipole vectors of the 1,2,4- (left) and the 1,3,4-(right) oxadiazole isomers.3  Although there are several compounds containing oxadiazoles in late-stage 
clinical testing today, there exists one prominent oxadiazole-containing pharmaceutical 
currently being distributed. Raltegravir (Figure 4) is an integrase transfer inhibiting drug 
containing a 1,3,4-oxadiazole, approved by the FDA in 2011 for the treatment of 
 
Figure 4. Raltegravir 
 
human immunodeficiency virus (HIV) in both adults and children.6  Raltegravir is both a 
potent and selective inhibitor of the strand transfer catalytic activity of one of the three 
enzymes involved in the replication of viral DNA.  The outcome of treatment with 
Raltegravir is the prevention of viral DNA from integration into the human genome. In 
addition to the inhibition of HIV-1 replication, Raltegravir has also been shown to inhibit 
the infection of an additional twenty-three isolates of HIV-1, while maintaining 
selectivity in regards to the inhibition of human phosphoryl transferases, including DNA 
polymerases. The 1,3,4-oxadiazole, along with the fluorobenzene ring, assist in the 
5  
coordination of water molecules to HIV-1 integrase. Molecular thermodynamics studies 
have revealed that the two nitrogen atoms in the 1,3,4-oxadiazoles are favorable 
hydrogen bonding acceptors, even more than that of the oxygen atom in the ring, and as a 
result they are able to contribute favorably to the ligand interactions between the donor 
oxygen atom in water and the cationic portion of the enzyme. It is in this way that the 
water-mediated interaction with a positively-charged complex in HIV-1 integrase is 
believed to be an important factor in the inhibition of integrase activity and viral 
replication.7   
 In addition to its use as a hydrogen-bonding substituent in Raltegravir, 1,3,4-
oxadiazoles are also being introduced into drug discovery programs for other purposes. 
Due to their ability to contribute favorably to ligand binding as discussed previously, 
1,3,4-oxadiazoles are increasingly being incorporated into the pharmacophore (the 
components of a drug molecule which assist with coordination to the target site) due to 
their ability to mimic aromatic linkers and arrange substituents into a planar arrangement, 
as well as temperament of molecular properties through ligand-cation interactions. Due to 
their similar charge distributions, 1,3,4-oxadiazoles have been used as replacements for 
esters, amides, carbamates, and hydroxamide esters within various bioorganic structures.3 
Where smaller functional groups with similar charge distribution but lower metabolic 
stability have the potential to be metabolized rapidly by the enzymes in the human body, 
1,3,4-oxadiazoles might be favored over those functional groups because of their more 
favorable metabolic stability.  
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1.2 Overview of Pharmacokinetic Parameters 
 In the process of determining a molecule’s capacity for use as a drug, there are 
many factors to consider aside from metabolic stability, including bioavailability, the 
nature of the target site, toxicity and adverse side effects, potency, and 
pharmacokinetics.8 Fundamentally, drug discovery programs seek to optimize the ADME 
(adsorption, distribution, metabolism, and excretion) properties of potential medicinal 
compounds, while simultaneously being able to balance potency of a drug with a 
reasonable dosing regimen. The pharmacokinetic profile of a drug describes how its 
effects within the body are compared with the amount of that drug remaining in 
circulation.8 The four fundamental pharmacokinetic parameters necessary for 
characterizing a drug’s passage through the body are clearance, volume of distribution, 
half-life, and bioavailability. The bioavailability of a drug is determined by the mode of 
administration, whether it be orally, intravenously, inspiratorily, etc.9  It is defined as the 
fraction of an unchanged drug that is absorbed intact and reaches the site of action 
following administration8. The solubility of a compound has an effect on the preferred 
mode of administration, with an intermediate level of water solubility preferred for drugs 
which will be administered orally.  Drugs which have lower water solubility/increased 
lipophilicity run the risk of decreased absorption following oral administration, and are 
extremely susceptible to rapid metabolism through hydrophobic absorptive surfaces of 
cell membranes. Conversely, drugs which are too soluble in water will have poor 
absorption across the gastrointestinal tract and will most likely pass through the body 
unchanged.10 Drug solubility is determined by the thermodynamic relationships between 
the solute and the solvent, specifically, the energy required to overcome the strength of 
7  
intermolecular forces in the solute solid-state and the energy generated upon the 
interaction of solute and solvent. A polar molecule is able to dissolve in a polar solvent 
(i.e., water) because the strength of the interactions between the solute and solvent are 
much larger than the intramolecular interactions holding the solute and solvent molecules 
together. For nonpolar molecules trying to dissolve in a polar solvent, the strong covalent 
interactions holding the molecule together cannot be overcome by the interactions 
between solute and solvent, and so the solute remains as a precipitate in solution.11 
There exist a number of strategies that chemists employ to improve the aqueous 
solubility of potential drug components. Suspension of the active ingredients in a drug 
within a medium of the optimal solubility properties, such as gel capsules, allows drug 
molecules which show poor water solubility to be dissolved in the capsule. When the 
capsule is ingested, it is metabolized by the body first, allowing the unchanged drug to be 
entered into circulation. Isolation of the salt forms of a drug, or its cocrystals, by 
modifying the suspension pH of a molecule enhances the solubility of a weakly acidic or 
basic drug in a polar solvent such as water.12 In addition to these suspension techniques, 
modification of the drug structure itself with bioisosteres13 (molecules with different 
physical properties which will produce the same biological outcomes) can also improve 
the solubility profile of a drug. In creation of the ferrocene/oxadiazole complex that this 
research aims to do, the structure of the starting thiosemicarbazide will be altered in order 
to change the aqueous solubility of the resulting molecule. 
 
. 
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1.3 Properties and Applications of Ferrocene and its Derivatives 
 Ferrocene is an organometallic compound consisting of ferrous iron (Fe2+) 
sandwiched between two flat, parallel cyclopentadienyl rings. It’s “accidental” discovery 
in 1952 by researchers attempting to form a cyclopentadienyl radical through treatment 
with ferric chloride led to a renewed interest in organometallic chemistry and its 
subdisciplines, as well as the Nobel Prize in Chemistry for its discoverers. Today, its 
commercial availability and the ease with which the cyclopentadienyl rings can be 
functionalized has led ferrocene to be one of the most studied of the sandwich 
complexes.14 As purchased, ferrocene is a yellowish-orange powder, which forms dark 
orange needle-like crystals upon sublimation. The compound itself can be easily modified 
through single electron oxidation reactions on the iron atom, electrophilic aromatic 
substitution on the cyclopentadienyl rings, or oxidized in the presence of acidic media to 
form stable, water-soluble ferrocenium salts. Owing to its favorable electrochemical 
properties, including high electron transfer rate, low redox potential, and stability of both 
ferrocene (Fe2+) and ferrocenium (Fe3+), ferrocene derivatives are frequently used as 
electrochemical sensors for DNA and proteins.15 Furthermore, ferrocene is stable in a 
variety of biological media, yet lipophilic enough to penetrate cell membranes rapidly, it 
melts at 173 °C without prior decomposition, and it demonstrates a diversified mode of 
reaction with biological substrates.16 
 The bioactive properties of ferrocene derivatives and their potential medicinal 
applications are well-known. Ferrocene and its derivatives are shown to demonstrate 
antiproliferative, anticancer, and antimicrobial properties. Ferrocerone (shown in Figure 
9  
5) is an example of a ferrocene drug currently used in clinical practice which is used for 
the treatment of diseases linked to iron deficiency.17  
 
 
Figure 5. Ferrocerone17 
Ferrocene-modified analogs of already prominent drugs including tamoxifen, which is 
used for the treatments of certain types of breast cancers, chloroquinone, which is used 
for the treatment of malaria, and other compounds which would otherwise have a high 
toxicity are currently undergoing clinical trials, with results demonstrating a similar if not 
improved potency over their commonly-used analogs.18 The decreased toxicity and the 
decreased likelihood of adverse drug reactions with these ferrocene analogs compared 
with more-well known drugs is a major reason for their continued exploration. In general, 
acyl derivatives of ferrocene tend to be slightly more toxic than their alkyl counterparts.19 
Furthermore, the oxidized forms of ferrocene were shown to be more bioactive than the 
neutral ones, which may mean that the cytotoxic properties of these compounds depend 
on the ability of the derivatives to generate reactive oxygen species which can degrade 
the cellular components of the tumor or pathogen.16 
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1.4 Previous Work with Ferrocene-Oxadiazole Complexes 
In previous work which explored the potential of using a ferrocene derivatized 
with a thiosemicarbazide for the detection of mercury (II) ion, the synthesis of a 
ferrocene/oxadiazole-containing compound was performed in two major steps: the 
reaction of ferrocene monocarboxylic acid with a thiosemicarbazide and the subsequent 
reaction of that structure with mercury (II) acetate.1 The reaction scheme of the ferrocene 
with the thiosemicarbazide and the subsequent attack of the sulfur with the mercury (II) 
ion are shown in pathways (i) and (vi) of Scheme 4 on page 12. The carboxylic acid of 
the ferrocene and the amide of the thiosemicarbazide are joined via amide coupling with 
HBTU, resulting in the formation of peptide bond and the expulsion of water from the 
compound. The second step shows the attack of the mercury on the sulfur, the 
precipitation from solution of HgS, and the subsequent cyclization of the sidechain to 
form the molecule of interest: a 1,3,4 oxadiazole. 
This research aims to build upon previous work by reacting the same starting 
material, ferrocene monocarboxylic acid with a series of different thiosemicarbazides. 
The goal of this research is to determine whether the reactions between the sulfur and the 
mercury can still occur and afford a cyclized oxadiazole product under the same 
conditions as the aforementioned schemes. The thiosemicarbazides will be selected on 
the basis of containing groups that enhances the medicinal properties of the entire 
molecule, including improvement of the molecule’s pharmacokinetic profile8, aqueous 
solubility12, or metabolic stability.20  
A careful investigation and selection of the thiosemicarbazides is of the utmost 
importance in order to carry out the derivatization of the ferrocene and the formation of a 
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novel ferrocene-oxadiazole compound. A general procedure would involve the systematic 
selection and testing of a variety of thiosemicarbazides to see, first and foremost, whether 
or not functionalization of the ferrocene can occur and whether or not the resulting 
structure can be worked up to produce an oxadiazole. The influence of a sulfur and 
peptide structure which reacts with the ferrocene has been shown to have little effect on 
the rate at which HgS precipitates out of solution, a phenomenon which has not been 
observed with other metal cations.21 Additionally, the cyclization of 
acylthiosemicarbazides to oxadiazoles stemming from a reaction with mercury (II) has 
been shown to occur under mild reaction conditions, with the achievement of high yields 
of oxadiazoles.22 The precipitation of HgS out of the reactant and the subsequent 
oxadiazole formation is a thermodynamically favorable process, and therefore should 
occur under a variety of reaction conditions. Therefore, the biggest challenge facing this 
research is most likely to arise during the amide coupling portion of the synthesis.  
              Ultimately, the employment of spectroscopic techniques will be used to 
determine the nature of the final product. Proton nuclear magnetic resonance 
spectroscopy will be used to elucidate the structure and chemical environment of certain 
molecules by measuring the response of a nucleus to a change in an external magnetic 
field, quantized through a value known as chemical shift. Chemical shifts are a 
characteristic of certain functional groups, and the peak splitting patterns of those shifts 
and integral values can be used to elucidate the structure of the product being analyzed.  
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Scheme 4. Structures of starting materials and products used for synthesis. (i), (ii), (iii): HBTU/triethylamine, 24 hrs. in acetonitrile.(iv):oxalyl chloride/pyridine cat., 2 hrs. in methlylene chlroride. (v):triethylamine, 16 hrs. in acetonitrile (vi): mercury acetate, 1 hr. in methanol.
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1.5 Partition Coefficients and Lipophilicity 
In addition to attempting to synthesize a novel oxadiazole-containing compound, 
the lipophilicity of each compound will also be determined. Lipophilicity is one of the 
key determinants of the pharmacokinetic behaviors of a drug, affecting the absorption of 
the drug into cells and tissues, the binding characteristics of the drug, and the solubility of 
the drug in blood, cerebrospinal fluid, and other media which are common medicinal 
targets. Therefore, an accurate determination of the lipophilicity of potential drug 
candidates is a high priority for medicinal chemists undertaking a drug design process. 
One of the oldest but most commonly used in vitro methods for determining the 
lipophilicity of any compound is by measuring an organic-aqueous partition coefficient 
of the compound.23 These values are typically reported as a numerical LogD, which is 
calculated according to the formula: 
 
 1-octanol and water are generally accepted as the most accurate two-phase system 
for modeling the partition coefficient between tissues and blood. The aqueous solution 
usually consists of a phosphate buffer prepared to pH 7.4 (the physiological pH of blood), 
and 1-octanol is the solvent that most closely mimics the chemistry of the phospholipid 
bilayer of cell membranes.24 The distribution of the compound in each phase can be 
determined using a variety of methods, but most commonly, the shake-flask or stir-flask 
assay. In these methods, a small amount of the compound of interest is dissolved in a 
polar aprotic solvent (usually dimethyl sulfoxide), and then mixed in a test tube or vial 
containing equal portions of 1-octanol and aqueous buffer. The tube is then shaken for a 
period ranging from 2-24 hours, allowing the compound to equilibrate between the two 
14  
phases. After the shaking is complete, the phases are separated from each other and the 
concentration of the compound is analyzed using UV-Visible spectroscopy, HPLC, 
UPLC, or other analytical means.23  
 The optimal LogD value for a particular drug varies on the region of the body that 
drug is targeting, as shown in Table 1 below. 
Table 1. LogD values and their associated outcomes in vivo.25 
LogD Value Solubility in Blood GI Absorptivity <0 High Low 0-1 High High 2 Average Average >5 Low High  
Generally speaking, a compound will have a good balance between solubility in fluids 
and permeability through cell membranes if the LogD value is in the range from 0-3. For 
drugs which need to cross the blood-brain barrier, the LogD value should be somewhere 
around 2. Hydrophilic compounds have a LogD close to 0 will be readily soluble in blood 
but exhibit low permeability across the gastrointestinal tract or blood-brain barrier. 
Highly lipophilic compounds are those which have a LogD greater than 5, and are poorly 
soluble in blood, resulting in a high degree of plasma protein binding, resulting and 
extremely low oral bioavailability.25 
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2. MATERIALS AND METHODS 
Reagents.  Ferrocene monocarboxylic acid (97%) was purchased from Strem Chemicals, 
Inc.. Acetonitrile, ethyl acetate, methanol, ethyl ether anhydrous, methylene 
chloride,  and monobasic potassium phosphate (USP Grade) were all purchased from 
Fisher Scientific. Triethylamine (99.5%), N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-
yl)uronium hexafluorophosphate (HBTU, <98%), 4,4-dimethyl-3-thiosemicarbazide 
(98%), mercury (II) acetate (>98%), 1-octanol, oxalyl chloride ( ≥99%), 4-
phenylthiosemicarbazide (99%), 4-(3-nitrophenyl)-3-thiosemicarbazide, pentane, 
pyridine, dimethyl sulfoxide, and dibasic potassium phosphate (USP Grade) were all 
purchased from Sigma-Aldrich.  Deuterated dimethyl sulfoxide, d-acetonitrile, and d-
chloroform (99%) were purchased from Cambridge Isotope Laboratories, Inc. for use in 
proton NMR. Air-sensitive experiments were conducted under an atmosphere of pre-
purified nitrogen gas. All reagents used met or exceeded ACS Grade purity, and required 
no additional purification steps prior to use.  
 Instrumentation.  A Varian Unity Plus Oxford 400 MHz NMR was used for all 1H 
NMR experiments. UV-Vis experiments were performed on a Perkin Elmer Lambda25 
Spectrophotometer. All compounds were weighed using a Mettler AE50 analytical 
balance. 
 2.1 Synthesis of 1-ferrocenoyl-4,4-dimethyl-3-thiosemicarbazide (Compound 3). 
Ferrocene monocarboxylic acid, 1, (0.5718 g, 2.5 mmol) was dissolved in 25 mL 
of acetonitrile in a 150-mL Erlenmeyer flask. The flask was equipped with a magnetic 
stir bar and stirred for 1 minute to promote dissolving of the solute. Triethylamine (180 
16  
μL, 2.5 mmol) was added to this solution, causing a color change from a pale orange to 
deep red. HBTU (0.9526 g, 2.5 mmol) was added directly to the flask and allowed to stir 
for 15 minutes. 4,4-dimethyl-3-thiosemicarbazide, 2, (0.2998 g, 2.5 mmol) was then 
added to the flask, along with an additional 180 μL of triethylamine, before the flask was 
capped and allowed to stir for an additional 24 hours. During that time, the color of the 
solution changed from a very deep red to a dark brown.        
Following the 24-hour stir period, the flask was removed from the stir plate. The 
solution in the flask was a deep brown color, with visible light brown precipitate settled 
on the bottom of the flask. The acetonitrile was decanted from the flask, and the 
remaining precipitate was washed twice with 30 mL of ethyl acetate. The ethyl acetate 
was added to the flask, swirled gently for 30 seconds, and then the resulting brown liquid 
drawn out of the flask with a Pasteur pipette, leaving behind a light brown powder. After 
the second wash, the powder was dissolved in 10 mL of dimethyl sulfoxide, and re-
precipitated using 5 mL of distilled water. The addition of the water to the organic 
solution caused bright-orange solids to aggregate in the bottom of the flask. The solution 
was filtered with a long-stem funnel and the precipitate was left to dry on the filter paper. 
After 48 hours of drying, the crude product, 3, (0.54 grams, 60%) was 
recrystallized in methanol. The tan precipitate was transferred from the filter paper to a 
150-mL Erlenmeyer flask containing 80 mL of methanol. The flask was then submerged 
into a beaker on a hot plate containing distilled water, and the methanol was heated to 
boil for approximately 15 minutes, with the flask being occasionally removed from the 
beaker and swirled to prevent buildup of precipitate on the walls of the flask. After all of 
the product had dissolved in the methanol, the solution was filtered hot through a long 
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stem funnel. The resulting orange filtrate was collected in a 100 mL Erlenmeyer flask and 
returned to the hot water bath, where the methanol was allowed to boil off of the solution. 
After 20 minutes, the solution had condensed enough where some small reddish-orange 
crystals were visible in the flask. The solution was removed from the hot water bath and 
allowed to cool to room temperature before being submerged in a beaker of crushed ice 
in the freezer. Following crystal formation after approximately 30 minutes in the ice bath, 
the liquid was decanted from the flask and the remaining reddish-orange crystals were 
washed with 5 mL of cold methanol five times. After the fifth wash, the methanol 
remained almost clear after swirling the crystals. The crystals in the flask were dried by 
lightly blowing nitrogen gas on the surface of the crystals from a needle. The crystals 
were then allowed to dry in a desiccator for 48 hours before weighing (0.055 g, 6%) and 
spectroscopic analysis using 1H NMR. 
 2.2 Synthesis of N,N-dimethyl(5-ferrocenoyl-1,3,4,-oxadiazol-2-yl)amine  
(Compound 4). 
Recrystallized Compound 3 (0.05 grams, 1.5 mmol) was placed into a 150-mL 
Erlenmeyer flask and set to stir on a magnetic stir plate with 90 mL of methanol. Once 
the ferrocene had dissolved, mercury (II) acetate (0.479 grams, 1.5 mmol) was added to 
the flask, and the solution was allowed to stir for 1 hour. Following the stir period, the 
solution was transferred to a 100 mL Schlenk flask, and the methanol was evaporated 
using a vacuum pump. Once all of the solvent had been evaporated, the remaining 
yellowish-brown residue on the walls of the flask was suspended in 10 mL of anhydrous 
ethyl ether, and then filtered using gravity filtration in a long-stem funnel. The orange 
filtrate was collected in a Schlenk flask and dried again using the vacuum pump. 
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To purify the final product and to remove any unreacted starting material, the 
dried product was extracted twice with distilled water. Ethyl acetate (50 mL) was added 
to the Schlenk flask to dissolve the product, and the resulting yellow solution poured into 
a 125 mL separatory funnel. Distilled water extractions of 50 mL were performed twice, 
and the aqueous layer was discarded. The organic layer, which was a bright yellow color, 
was poured into a beaker and left to dry for 24 hours. Returning to the beaker the next 
day, all of the ethyl acetate had evaporated off, leaving behind a series of small, red 
spindle-shaped crystals. The crystals, 4, (0.0035 grams, 7%) were easily scraped from the 
bottom of the flask, and analyzed using 1H NMR.  
 
2.3 LogD Determination of Oxadiazole 
Recrystallized Compound 4 (0.0035 grams) was dissolved in 50 μL of dimethyl 
sulfoxide, and pipetted into a vial containing 1000 μL of 1-octanol and 1000 μL of 10 
mM aqueous phosphate buffer adjusted to pH 7.4. The buffer was prepared by combining 
potassium phosphate monobasic (0.0152 grams, 0.11 mmol) and potassium phosphate 
dibasic (0.0680 grams, 0.39 mmol) in a 100 mL volumetric flask and diluting to the mark 
with distilled water. To compensate for the absence of a mechanical shaker, the vial 
containing the compound and both phases was capped and shaken manually for one hour 
before being placed in the centrifuge for five and a half hours. The tube was removed 
from the centrifuge and the aqueous (bottom) and organic (top) layers were separated 
from each other using a separatory funnel. The two solutions were then transferred 
separately to a 1 mL cuvette and analyzed using UV-Visible spectroscopy. Prior to 
obtaining the scans of the phases, the machine was blanked using a cuvette containing 1 
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mL of 1-octanol and another containing 1 mL of the phosphate buffer. The scans for 4 in 
each of the two phases were superimposed and are shown in Figure 25 of the Results 
section. 
In order to determine the concentrations in each of the phases, calibration curves 
of 4 in both 1-octanol and phosphate buffer were constructed in order to calculate the 
extinction coefficient in each solution. The procedures for making each calibration curve 
was identical. Compound 4 (2 mmol) was dissolved in 50 μL of dimethyl sulfoxide, and 
then suspended in 3.5 mL of the solution being analyzed. This initial concentration of 2 
mM was analyzed using UV-Vis spectroscopy. The subsequent four dilutions were made 
through serial dilutions. In order to gauge the responsiveness of absorbance to changes in 
concentration, the second dilution was prepared by drawing 3 mL of the stock solution 
into a 5-mL syringe and diluting that solution to a new concentration of 1.7 mM by 
adding 0.5 mL of 1-octanol or buffer. After this second scan, the subsequent three 
dilutions were made through a twofold dilution procedure. The more concentrated 
solution was combined with buffer/octanol in a 1.75 mL to 1.75 mL ratio, until five total 
dilutions for each phase were scanned. The results for each phase were completed in 
triplicate, using the same quantity of starting material. The three scan results for each 
phase are shown in Figures 17-22. The calibration curves for each phase were made by 
plotting the absorbance at the maximum wavelength (444 nm) as a function of the 
average concentration between the three trials, and are shown in Figures 23 and 24.  
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2.4 Attempted Synthesis of 1-ferrocenoyl-4-phenylthiosemicarbazide (Compound 6) 
via HBTU Coupling 
 Compound 1 (0.19 grams, 1.7 mmol) was dissolved in 10 mL of acetonitrile and 
placed in a 100-mL Erlenmeyer flask equipped with a stir bar. As the solution was being 
stirred, triethylamine (60 μL, 1.7 mmol) was added to the solution, changing the color 
from a bright orange to a red. To this stirring solution, HBTU (0.316 grams) was added, 
and the solution continued to stir at room temperature for 20 minutes. Following the stir 
period, 4-phenylthiosemicarbazide, 5, (0.14 grams, 1.7 mmol) was added, along with 
another 60 μL aliquot of triethylamine. The flask was capped and allowed to stir at room 
temperature for 24 hours. 
After the overnight stir period, the flask was examined for precipitate buildup. 
Over the course of the stir period, a dark brown precipitate had built up along the walls of 
the flask, and the liquid portion had turned a dark brownish-green color. The contents of 
the flask were washed with ethyl acetate (30 mL x 3), and the remaining liquid drawn off 
and put into another beaker. The residual brown precipitate was then diluted with 
approximately 15 mL of DMSO and 10 mL of water. Unlike previous synthesis attempts, 
the addition of water did not cause the precipitation of solid out of the DMSO. A solvent 
extraction of diethyl ether (25 mL x 2) was attempted on the DMSO solution, but the 
product remained dissolved. Additionally, another 25 mL of water was added to the 
DMSO solution to try and drive out the precipitate, but no solids had formed after an 
hour in the ice bath. After a failed attempt to remove the liquid using a vacuum pump, the 
solution was discarded. 
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Recovery of the product from the acetonitrile/ethyl acetate extracts from the 
initial reaction solvent was accomplished by pouring the solution into a flask, submerging 
the flask in a beaker of cold water, and cooled in the refrigerator overnight. In the 
morning, some brown precipitate identical to the precipitate in the flask was observed 
following the 24-hour stir period. The liquid was drawn out of the flask, and the solid 
product was washed with hexanes (10 mL) and diethyl ether (10 mL x 2). The solid was 
dried using a needle blowing nitrogen gas, and the crude product (0.05 grams) was 
analyzed using 1H NMR. The remaining product was recrystallized in hot methanol, 
leaving behind a very small amount (< 0.003 grams) of fine, orange needles, 6, that were 
analyzed using 1H NMR. 
A second procedure with double the quantities of starting materials was attempted 
as well with a modified workup procedure. The ethyl acetate/acetonitrile washes obtained 
following the stir period were dried in vacuo, leaving behind a thick, gooey residue on 
the interior of the Schlenk flask. The residue was washed with diethyl ether (25 mL x 3), 
and the bright orange ether fractions were pooled in a beaker and set aside to dry. The 
remaining residue in the flask was dissolved in methanol, and a recrystallization was 
attempted. During the heating process, the methanol solution turned a clear deep red, and 
during filtering, a large quantity of black/brown precipitate was retained on the filter 
paper. Following filtration, the filtrate was once again heated to evaporate some of the 
methanol. Once the volume had been reduced to approximately 5 mL, and no 
condensation of the product has occurred in the solution, 5 drops of distilled water were 
added to the flask and reheated. The addition of water yielded a black/brown precipitate, 
which was isolated from the liquid using a Büchner funnel and analyzed using 1H NMR. 
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The ether extracts, after drying in a vacuum, yielded an orange oil on the walls of the 
flask. The oil was analyzed using 1H NMR, and an attempted recrystallization of the 
residue in methanol yielded the same blackish/brown powder identical to the other 
extracts. 
 
2.5 Attempted Synthesis of Compound 6 Using a Carbonyl Chloride Intermediate 
The preparation of ferrocene carbonyl chloride was adapted from a similar 
procedure by Lapic et. al.26 The synthesis was conducted under a nitrogen atmosphere. 
Compound 1 (600 mg, 2.6 mmol) was dispensed into a Schlenk flask equipped with a stir 
bar and an exit needle. The exit needle was connected to a solvent trap, and, with a 
second needle, nitrogen gas was blown into the flask for 5 minutes to remove excess air 
and moisture. Simultaneously, 30 mL of methylene chloride were dispensed into a round-
bottom flask, and nitrogen gas was bubbled through the liquid for 15 minutes. Using a 
cannula, approximately 15 mL of the degassed (oxygen and water-free) methylene 
chloride was transferred to the Schlenk flask. Using a plastic syringe, 0.54 mL of oxalyl 
chloride were dispensed through the septa into the flask, along with 2 drops of pyridine, 
causing the solution to turn from a pale yellow to a dark red and bubble vigorously. The 
flask was then connected to a condenser, and allowed to gently reflux for two hours on a 
heating mantle.  Following the reflux period, the contents of the flask were dried in vacuo 
to yield a dark red oil. The oil was gently heated on the mantle and washed with 
petroleum ether (15 mL x 3) and pentane (10 mL x 2). The resulting blackish-brown 
residue was discarded, and the dark red extracts were pooled and dried again in vacuo to 
yield another red oil. In order to estimate a mass of the oil for further synthetic steps, the 
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oil was re-dissolved in methylene chloride, poured into a flask of known weight, and 
evaporated. A small portion of this re-evaporated compound, was used for 1H NMR. 
The product, ferrocene carbonyl chloride, 7, (0.553 grams, 2.22 mmol) was 
redissolved in 15 mL of methylene chloride and set to stir on a magnetic plate. A solution 
of Compound 5 (0.37 grams, 2.22 mmol) dissolved in 10 mL was poured into the 
carbonyl chloride along with triethylamine (0.69 mL, 5 mmol). The solution was covered 
with a septum and allowed to stir for 24 hours. The resulting dark brown-reddish liquid in 
the flask was transferred to a separatory funnel and extracted with a saturated sodium 
bicarbonate solution (20 mL x 3), followed by a wash with distilled water (20 mL x 2). 
The yellow extracts of the aqueous layer were pooled and left to dry. The brown organic 
layer was dried in vacuo, suspended in methanol, and recrystallization was attempted. 
Although some of the residual powder immediately dissolved in the methanol upon 
heating, the methanol solution still appeared slightly cloudy even after the methanol had 
been heated to its boiling point. The first filtering of the solution yielded a yellow filtrate, 
with a large amount of black powder retained on the paper. The black powder was 
reserved for 1H NMR. The yellow filtrate was heated slowly to boiling, filtered again, 
and then both solutions were dried in vacuo and analyzed using 1H NMR. 
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2.6 Attempted Synthesis of 1-ferrocenoyl-4-(3-nitrophenyl)-3-thiosemicarbazide 
Compound 1 (0.023 grams, 0.43 mmol) was dissolved in 10 mL of acetonitrile 
and 15 μL of triethylamine (0.43 mmol) and stirred on a magnetic plate. HBTU (0.43 
grams, 0.43 mmol) was added to this mixture and allowed to stir for 15 minutes. After 
stirring, 4-(3-nitrophenyl)-3-thiosemicarbazide, 8, (0.092, 1.75 mmol) were added to this 
solution along with another 15 μL aliquot of triethylamine, and the solution continued to 
stir covered for 36 hours. After the stirring period, the dark brown liquid contents of the 
flask were removed with a Pasteur pipette, and the residual beige solid was diluted with 
10 mL of ethyl acetate and withdrawn. The ethyl acetate wash was repeated two more 
times, during which the wash color changed from dark brown, to yellow, to almost 
colorless by the third wash. The pale orange precipitate was dried using nitrogen 
dispensed from a needle, and analyzed using 1H NMR. The precipitate was then 
recrystallized using methanol, yielding bright orange crystals which were analyzed using 
proton NMR. 
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3. RESULTS AND DISCUSSION  3.1 Synthesis of Oxadiazole  Figures 6-11 show the structures and NMRs of the starting materials used in the 
synthesis of the compounds shown in Scheme 4. Since the 1H NMR of each compound in 
this synthesis was taken in DMSO-d6, all of the spectra contain a solvent peak at 2.5 
ppm, with a water peak appearing in the spectra at 3.3 ppm. Ferrocene monocarboxylic 
was the only starting material stored at room temperatures. HBTU and 4,4-dimethyl-3-
thiosemicarbazide were stored in plastic bags in the refrigerator due to air-sensitivity. The 
peak assignments and integrations for all three starting materials are shown in Table 2. 
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 Figure 6. Structure of Compound 1.  
 Figure 7. 1H NMR of Compound 1 in DMSO-d6     
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.   Figure 8. Structure of Compound 2.   
 Figure 9. 1H NMR of Compound 2 in DMSO-d6.         
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 Figure 10. Structure of HBTU  
 Figure 11. 1H NMR of HBTU in DMSO-d6.   As evidenced by the three small peaks in the 4-5 ppm range which are 
characteristic of a monosubstituted ferrocene, there was a small amount of contamination 
in this particular bottle of HBTU from the ferrocene monocarboxylic acid. This impurity 
persisted in the NMR even though multiple scans of different HBTU samples were taken, 
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meaning that the impurity was likely present in the entire bottle of HBTU. The trace 
amounts of Compound 1 in the HBTU, however, did not have any noticeably adverse 
effects on the synthesis.  
 Table 2. Chemical shifts of starting materials used in preparation 
 Assignment Chemical Shift (ppm) Integration Theoretical Integration 
  Compound 1 (Figure 7) 
Ha 4.22 (s) 4.80 5 
Hb 4.44 (t) 2.00 2 
Hc 4.71 (t) 2.00 2 
Hd 12.15 (bs) 1.00 1 
Compound 2 (Figure 9)  Ha  3.10 (s)  6.00  6 
 HBTU (Figure 11) 
Ha 3.40 (s) 4.11 3 
Hb 3.03 (s) 4.05 3 
Hc 8.12 (dt) 1.00 1 
Hd 7.71 (m) 1.17 1 
He 7.85(dt) 1.03 1 
Hf 7.97 (m) 1.18 1 
   Since none of the starting materials underwent any type of purification process, 
the integration values did not exactly match the theoretical values expected based on 
assignment of nonequivalent protons. These discrepancies with the integration did not 
change the overall outcomes of the synthesis as it proceeded. 
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  Figure 12. Structure of Compound 3.  
  Figure 13. 1H NMR of crude Compound 3 in DMSO-d6.     
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 Figure 14. 1H NMR of Compound 3 (recrystallized in methanol) in DMSO-d6    Based upon what is known about the reaction mechanism between the ferrocene 
reactant and the thiosemicarbazide, the only peak that ought to have disappeared between 
the structures of the starting materials and the reactants is the OH proton, which appeared 
at 12.15 ppm in the NMR shown in Figure 7. As shown in Figures 13 and 14, that peak 
did disappear, meaning that the dehydration reaction did occur and a new amide bond 
was formed. The NMRs of the products also displayed two new singlets between 9 and 
10 ppm. These singlets represent the two nonequivalent -NH groups formed during the 
dehydration reaction. The most downfield singlet signifies the -NH proton closest to the 
carbonyl carbon, positioned so due to greater deshielding  by the more electronegative 
oxygen compared with the sulfur. The spacing between the peaks of the monosubstituted 
ferrocene also decreased, in particular, the peaks showing the five unsubstituted 
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cyclopentadienyl ring protons and the two equivalent protons furthest away from the 
carbonyl group. This difference in spacing occurs due to the increased shielding of the 
protons on the unsubstituted Cp ring due to a less polar side chain on the ferrocene. Since 
the bulky thiosemicarbazide now attached to the ferrocene has some electron-donating 
properties, the Hb protons appear more upfield than they did in the starting material. 
 The differences between the crude product and the recrystallized product are 
minimal. The only observable difference between these two spectra is the emergence of a 
small singlet around 3.1 ppm in Figure 14, just upfield from the water peak. This trace 
impurity in the spectra is most likely due to some residual methanol in the crystals. In an 
NMR sample where the solvent is DMSO, trace amounts of methanol will resonate at 
chemical shift of 3.13 ppm and 4.01 ppm.27 
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 Figure 15. Structure of Compound 4.   
  Figure 16. 1H NMR of Compound 4 in DMSO-d6.        
34  
Table 3. Chemical shifts of reaction products from oxadiazole synthesis. 
 Assignment Chemical Shift (ppm) Integration Theoretical Integration 
   Compound 3  crude (Figure 13) 
Ha 4.87 (t) 2.00 2 
Hb 4.37 (t) 2.04 2 
Hc 4.32 (s) 4.90 5 
Hd 9.71 (s) 0.79 1 
He 9.24 (s) 0.79 1 
Hf 3.23 (s) 6.06 6 
   Compound 3 recrystallized (Figure 14)   
Ha 4.87 (t) 1.90 2 
Hb 4.37 (t) 1.80 2 
Hc 4.32 (s) 4.02 5 
Hd 9.69 (s) 1.00 1 
He 9.24 (s) 0.97 1 
Hf 3.23 (s) 5.40 6 
  Compound 4 Fc-oxadiazole (Figure 16) 
Ha 4.83 (t) 2.69 2 
Hb 4.52 (t) 2.67 2 
Hc 4.26 (s) 5.41 5 
Hd 3.08 (s) 6.01 6 
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The intramolecular cyclization of the purified Fc-thiosemicarbazide structure shown in 
Figure 12, yielding the final oxadiazole product shown in Figure 15, caused a drastic 
change in the number of peaks observed in the oxadiazole NMR shown in Figure 16. The 
amide protons, which resonated in the 9-10 ppm range of Figures 13 and 14 completely 
disappeared, and the six resonating -CH3 protons shifted downfield from 5.40 ppm in the 
recrystallized Fc- thiosemicarbazide to 6.01 ppm in the Fc-oxadiazole product. The 
spacing between the Hb and Hc in the product also increased, due to the diminished 
electron-withdrawing effects of the carbonyl carbon the substituted cyclopentadienyl ring 
protons. As expected, the integrations of the resonating protons did not change 
drastically.  
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3.2 Lipophilicity (LogD) of Oxadiazole   Figures 17-22 show the UV-Vis scans of Compound 4 in 1-octanol (Figures 17-
19) and aqueous phosphate buffer at pH 7.39 (Figures 20-22) at five different 
concentrations. The scans of the compound in each solution were run in triplicate. 
 Figure 17. UV-Vis of Compound 4 in 1-octanol (Trial 1).  
 Figure 18. UV-Vis of Compound 4 in 1-octanol (Trial 2) 
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 Figure 19. UV-Vis of Compound 4 in 1-octanol (Trial 3)    
Figure 20. UV-Vis of Compound 4 in phosphate buffer (Trial 1) 
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 Figure 21. UV-Vis of Compound 4 in phosphate buffer (Trial 2)  
 Figure 22. UV-Vis of Compound 4 in phosphate buffer (Trial 3)      
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The maximum absorbance in each of the six scans was found to be approximately 444 
nm. The absorbances at 444 nm in each scan are shown in Table 4. From that 
information, calibration curves for the five concentrations in each phase were constructed 
and shown in Figures 23 and 24. The Y error bars on the graphs represent the standard 
deviation of the absorbances among the three trials. Since the spectrometer was blanked 
twice before each scan was taken (once with an air blank and once with the stock solution 
without analyte), and because Beer’s Law assumes that a solution with no dissolved 
analyte will have 100% transmittance (i.e., no absorbance), the trendlines for the 
calibration curves were forced through the origin. 
The Beer-Lambert Law is a commonly-used equation in UV-Visible spectroscopy 
which relates the absorbance of a compound with its molar concentration, the path length 
of the cuvette, and the extinction coefficient of that compound in a particular solvent. The 
equation for absorbance is written as: 
 
 where A is the absorbance of the compound at a particular wavelength, b is the 
path length of the cuvette (in cm), and c is the concentration of the solution (in M). The 
extinction coefficient, ε, also known as molar absorptivity, is a characteristic of a 
compound at a specific wavelength in a specific solvent. Its value corresponds to the 
allowed-ness of the electronic transitions that the compound undergoes in the presence of 
UV radiation. Pure ferrocene, which absorbs at approximately 440 nm, undergoes a d to d 
electron transition.28 In an organic solvent such as cyclohexane, this results in a molar 
absorptivity of 96 M-1cm-1.29 
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According to this law, the equation of the line of best fit obtained from a 
calibration curve can be used to determine the extinction coefficient of a compound. 
 
 Figure 23. Calibration curve of Compound 4 in 1-octanol.  Trendline: y=488.625x (R2 = 0.967) 
 Figure 24. Calibration curve of Compound 4 in phosphate buffer Trendline: y=558.945x (R2 = 0.949)      
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Table 4. UV-Vis Absorbances and Concentrations at 444 nm. 
 Concentration  (M) Trial 1  Abs. Trial 2  Abs. Trial 3  Abs. Average Abs. S.D. 
    1-octanol 
2.00 x 10-3 1.053 1.181 1.211 1.148 0.086 
1.70 x 10-3 0.520 0.723 0.717 0.654 0.115 
8.40 x 10-4 0.251 0.417 0.414 0.361 0.095 
4.20 x 10-4 0.142 0.229 0.229 0.200 0.050 
2.10 x 10-4 0.066 0.147 0.134 0.117 0.044 
    Phosphate buffer 
2.00 x 10-3 1.082 0.775 2.251 1.370 0.779 
1.70 x 10-3 0.562 0.379 1.204 0.715 0.433 
8.40 x 10-4 0.262 0.206 0.639 0.370 0.235 
4.20 x 10-4 0.136 0.112 0.329 0.193 0.119 
2.10 x 10-4 0.067 0.061 0.190 0.106 0.073 
 The results of the modified shake-flask procedure are shown below in Figure 25. 
  Figure 25. UV-Vis of organic and aqueous partitioning of Compound 4 (λmax = 441 nm)    
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Figure 26. UV-Vis of the aqueous layer following partitioning. 
 
Closer inspection of Figure 25 reveals the limited partitioning of Compound 4 in 
the aqueous layer compared with the organic layer. A calculation to estimate the number 
of moles in the organic phase was performed using the absorbance obtained at 444 nm in 
Figure 25 and the extinction coefficient calculated using data from Figure 23. This 
calculation resulted in an estimated 0.018 mmol of Compound 4 dissolved in the organic 
layer at the time of analysis. Considering that a total amount of 0.012 mmol of 4 were 
used for the partitioning in the experiment, we can be fairly certain that almost all of the 
compound has been partitioned into the organic layer. Inspection of Figure 26 confirms 
this observation, since there appears to be no appreciable absorbance at 444 nm. Any 
discrepancies between this calculated amount and the amount put into the system initially 
can be attributed to errors in the determination of the extinction coefficient. 
Additionally, further analysis of the plot showing just the aqueous layer (shown in 
Figure 26) can be used to calculated a minimum LogD value for Compound 4. Inspection 
of the small peak appearing at approximately 450 nm yields a corrected absorbance of 
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0.00205, and a noise level of approximately 0.00083, resulting in a signal-to-noise ratio 
of about 2.5. We can bracket the minimum LogD value through an estimate of the limit 
of detection, which is given by a signal-to-noise ratio of the spectrum multiplied by 3.30 
This results in a minimum absorbance value in the aqueous phase of 0.00615. Inserting 
this minimum absorbance value into Beer’s Law yields the following concentration: 
 
 
 
Likewise, the concentration in the organic layer can be calculated as: 
 
Now that these concentrations are known, a lower limit on the LogD value can be 
estimated by: 
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This calculated LogD value at the detection limit of the compound in the aqueous 
layer means that, at a minimum, we can expect this compound to have a LogD value of 
1.21. Enhanced methods of detection which are better suited to detect small 
concentrations (HPLC or UPLC), or by replication of the experiment with a larger initial 
quantity of analyte would yield a value close to or even higher than the one calculated 
here. Furthermore, using a mechanical shaker for a period of 24 hours of longer might 
demonstrate different results from the ones obtained here in which the sample was shaken 
by hand or agitated using a centrifuge. However, based on this calculation and an 
observation of the partitioning, we can conclude that Compound 4 is preferentially 
partitioned into the octanol layer. According to the information given in Table 1, 
compounds with a high LogD value (those which are more lipophilic) will demonstrate 
low blood solubility and poor metabolic stability owing to gastrointestinal permeability. 
Future synthetic attempts, therefore, should be directed towards creating compounds with 
more polar or charged groups. 
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3.3 Attempted Synthesis of 1-ferrocenoyl-4-phenylthiosemicarbazide via HBTU Coupling 
 Figures 27 and 28 show the structure and 1H NMR, respectively, of Compound 5. 
The starting material was dissolved in deuterated DMSO, so the peaks at 2.5 ppm and 3.3 
ppm in the NMR reflect solvent and water, respectively. The three phenyl proton peaks 
can be seen in the NMR in the 7-8 ppm range, and have integrations values similar to the 
2:2:1 ratio that was expected. While the NMR displays a broad singlet around 4.8 ppm 
which would be characteristic of an -NH group, there appears to be a much sharper 
singlet around 9.1 ppm and an additional, low-intensity peak just upfield at 9.6 ppm. 
Because of its proximity to lower electronegativity groups such as the C=S bond and the 
phenyl group, Hc was assigned as the most upfield peak, and the Ha protons were 
assigned as the sharp singlet at 9.1 ppm.  
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 Figure 27. Structure of Compound 5.   
Figure 28. 1H NMR of Compound 5 in DMSO-d6. 
Based upon similarities between the initial structures of the starting materials and 
the mechanism of amide coupling employed by HBTU, the product structure of a reaction 
between Fc-monocarboxylic acid and 4-phenyl thiosemicarbazide was predicted to have a 
structure similar to the one shown in Figure 29. Figures 30-32 are the results of a first 
attempt at synthesizing and purifying this new compound through recrystallization. 
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Figure 29. Attempted product of reaction between 4-phenylthiosemicarbazide and ferrocenemonocarboxylic acid (Compound 6).     
 Figure 30. 1H NMR of crude Compound 6 in d-Acetonitrile.   
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 Figure 31. 1H NMR of Compound 6 in d-acetonitrile after recrystallization in methanol   
 Figure 32. 1H NMR of Compound 6 after the second methanol recrystallization in d-acetonitrile  
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 The peaks present in the sample of the crude product (Figure 30) demonstrate that 
the desired product might have actually been synthesized. The three characteristic peaks 
of a mono-substituted ferrocene are present in the 4-5 ppm range, all showing integration 
values similar to the 5:2:2 ratio that was expected. Similarly, the NMR of the crude 
product also showed the three peaks in the 7-8 ppm which closely resembled the 
positions of the three aromatic protons shown in the starting material. Additionally, the 
disappearance of at least one of the -NH peaks indicates that the amide coupling may 
have occurred as expected. The difficulty associated with analysis of the crude product is, 
since the yield was so low, the resolution of the peaks and the low signal-to-noise ratio 
made it difficult to discern the multiplicity of the peaks, as well as obtain accurate 
integrations. This challenge only increased when attempting to analyze the NMR of the 
first and second recrystallizations of the crude product in NMR. As seen in the resulting 
spectra in Figures 31 and 32, the signal-to-noise ratio of the peaks decreased so 
dramatically such that, after the second recrystallization, the none of the integrations or 
multiplicities of the aromatic protons in NMR could be obtained. Increasing the number 
of transients run by the NMR did little to improve the resolution of the peaks or the signal 
to noise ratio. Both of the spectra showing the product after each successive 
recrystallization were acquired with nt=100, which means that in order to see any 
significant improvement, the number of scans might have to be increased to 1000 or 
higher. The continued persistence of those phenyl peaks and the three ferrocene peaks 
through multiple recrystallizations indicates that the product was likely present in small 
quantities. Table 5 gives a summary of the chemical shifts of the thiosemicarbazide 
starting material and the products, both crude and recrystallized. 
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  Table 5. Chemical shifts of Fc-phenylthiosemicarbazide synthesis reactants and products. 
 Assignment Chemical Shift (ppm) Integration Theoretical Integration 
    Compound 5  (Figure 28) 
Ha 9.13 (bs) 1 2 
Hb 9.68 (s) 1 1 
Hc 4.79 (bs) 0.06 1 
Hd 7.63 (d) 2.16 2 
He 7.30 (t) 1.83 2 
Hf 7.09 (t) 1.02 1 
     Compound 6; crude. (Figure 30) 
Ha 4.24 (s) 5.00 5 
Hb 4.49 (t) 2.13 2 
Hc 4.83 (t) 2.11 2 
He 8.27 0.80 1 
Hg 7.62 2.08 2 
Hh 7.34 1.31 2 
Hi 7.06 0.28 1 
     Compound 6; recryst. (Figure 31) 
Ha 4.2 (d) 4.00 5 
Hb 4.48 (t) 2.54 2 
Hc 4.82 (t) 2.47 2 
He 8.27 1.86 1 
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Hg 7.58 2.24 2 
Hh 7.39 2.25 2 
Hi 7.06 1.49 1 
 Compound 6; second recryst.  (Figure 32) 
Ha 4.2 (s) 4.81 5 
Hb 4.48 (t) 1.89 2 
Hc 4.82 (t) 2.29 2 
    This particular trial of the synthesis, however, turned out to be the only attempt 
with results resembling the predicted structure of the final product. Following the first 
attempt at synthesis, the results of which are shown here, further attempts at synthesis 
yielded no compounds or spectra which remotely resembled the attempted product. 
Multiple trials were run in which the acetonitrile was evaporated to dryness immediately 
following the 24-hour stir period, followed by washes with ethyl acetate, ether, and 
hexane. This resulted in NMR spectra which were missing either the ferrocene peaks, the 
phenyl peaks, or both. It was proposed, at this point, that perhaps the HBTU was 
interacting with the aromatic protons of the thiosemicarbazide or one or more of the 
amine protons. These interactions would not have been witnessed in the coupling 
between the Compound 1 and Compound 2 because of the absence of such protons. In 
order to keep working with this promising starting material, an alternative method of 
synthesis would need to be determined that did not rely on a coupling agent. 
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  3.4 Attempted Synthesis of Compound 6 using a Carbonyl Chloride Intermediate   The structure of ferrocene carbonyl chloride, 7, is shown in Figure 33. The 
spectrum shown in Figure 34 is of the crude red oil obtained from the Schlenk flask. 
 
 Figure 33. Structure of Compound 7.   
  Figure 34. 1H NMR of Compound 7 in chloroform-d after washes with pet. ether and pentane.   
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The large singlet at 7.26 ppm can be attributed to the chloroform-d in which the sample 
was run. The two small singlets appearing from 7.5-8 ppm are most likely remnants of 
residual pyridine, which was used as a base catalyst during the reflux period. The two 
upfield singlets in the 0.5-1.5 ppm range are most likely due to trace amounts of pentane, 
which was used during the washing process and displays singlets at 0.88 and 1.27 ppm in 
chloroform. Furthermore, the four peaks within the 4-5 ppm range give some indication 
that a monosubstituted ferrocene is still present in the sample.  
 
 Figure 35. 1H NMR of Compound 7 in DMSO-d6 after recrystallization in chloroform-d.   Figure 35 shows the spectrum of a small sample of Compound 7 which was 
obtained from the test tube of the original NMR sample several days following its 
preparation. All of the chloroform-d had evaporated from the test tube, leaving behind a 
fine, grayish-brown powder in the bottom of the tube and a series of long, orange needles 
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which had grown up the side of the flask. NMR of a few of these crystals in DMSO 
revealed an incredibly clean spectrum, with three peaks in the 4-5 ppm range which 
integrated almost exactly to the values expected for the ferrocene compound. The split 
peak at 4.2 ppm, which ideally should have been a singlet, is the only indication that 
there are any impurities in this spectra. Furthermore, the chemical shifts of those three 
peaks in Figure 35 allow this product to be distinguished from Compound 1’s spectrum 
shown in Figure 7. The three Cp proton peaks resonate at 4.3, 4.5, and 4.7 ppm in the 
carboxylic acid starting material, and shift to 4.2, 4.5, and 4.6 ppm in the spectrum of the 
carbonyl chloride. However, the extremely small size of recovered pure crystals (0.002 
grams) made it impossible to use this purified product for reaction with Compound 5, so 
the remnants of the red oil were used instead. Figures 36-38 show the crude product of 
this reaction, the product following the first recrystallization in methanol, and the product 
following the second recrystallization in methanol, respectively. 
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 Figure 36. 1H NMR of crude product from carbonyl chloride - phenylthiosemicarbazide synthesis in DMSO-d6.   
  Figure 37. 1H NMR of first recrystallization product in DMSO-d6.  
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 Figure 38. 1H NMR of second recrystallization product in DMSO-d6.   The resulting spectra from this synthesis, due to the large clusters of peaks and 
multiplets, don’t allow any specific conclusions to be made about the exact structure of 
the product. All three spectra, do however, contain clusters of peaks in certain regions 
which can be useful in generalizing the structures of the product. The clusters of peaks in 
the 4-5 ppm range and the 7-8 ppm range are, as mentioned before, characteristic of the 
monosubstituted ferrocene and the aromatic protons on the phenyl thiosemicarbazide, 
respectively. Since the solvent was evaporated from the reaction mixture with a vacuum 
immediately following the 24-hour reaction period, the abundance of peaks in the 0.5-2 
ppm range could be contributed by residual pentane (from the oil), petroleum ether, or 
both.  
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3.5 Attempted Synthesis of 1-ferrocenoyl-4-(3-nitrophenyl)-3-thiosemicarbazide   Figures 39-41 show the attempted synthesis of the product of Compound 1 acid with 4-
(3-nitrophenyl)-3-thiosemicarbazide, 8. The structure and NMR of the starting material 
are shown in Figures 39 and 40, respectively. 
 
Figure 39. Structure of Compound 8. 
 
Figure 40. 1H NMR of Compound 8 in DMSO-d6. 
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Figure 41. 1H NMR of crude Fc-nitrothiosemicarbazide product in DMSO-d6.  
 Figure 42. 1H NMR of product in DMSO-d6 recrystallized in methanol. 
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 The resulting spectra of this synthesis clearly show that the final product isolated 
product contains no traces of ferrocene monocarboxylic acid. Since this reaction was 
accomplished using HBTU, it is likely that the same issues which plagued the attempted 
synthesis of Compound 6 are present here. The HBTU seems unable to have initiated the 
dehydration reaction between the amine on the thiosemicarbazide and the carboxylic acid 
of the ferrocene. Since Compound 1 is much more hydrophobic and therefore much more 
soluble in acetonitrile compared with the relatively polar Compound 8, it is likely that the 
dark brown reaction liquid which was drawn off the flask and subsequently discarded 
contained the unreacted ferrocene. The subsequent washes with ethyl acetate, also a 
nonpolar solvent, probably removed all other traces of the monosubstituted ferrocene, 
which would account for why those peaks did not present themselves in the spectra of the 
product. Interestingly enough, the differences in the spectra between the starting material 
and the reaction products indicate that some chemistry was most likely worked on the 
aromatic protons of Compound 8. Although the overall positions of the peaks do not 
change from the crude product to the recrystallized material, we instead see two singlets 
appear at approximately 8.7 and 10.5 ppm, and two other multiplets appear at 7.6 and 7.8 
ppm.  
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4. CONCLUSIONS AND FUTURE WORK 
This research describes attempts at synthesizing a variety of novel oxadiazole-
containing compounds. The aqueous solubility of one such compound, N,N-dimethyl(5-
ferrocenoyl-1,3,4,-oxadiazol-2-yl)amine, was determined using a modified shake-flask 
procedure, which employed UV-Vis spectroscopy to quantify the amount of compound in 
each phase of an organic and aqueous solvent system. The results of the partition between 
1-octanol and an aqueous phosphate buffer resulted in a minimum estimated LogD value 
of 1.21, which indicates that this particular molecule could possibly demonstrate poor 
blood solubility and lower metabolic stability/high GI absorptivity. Furthermore, three 
other attempts were described here to derivatize ferrocene monocarboxylic acid with two 
aromatic thiosemicarbazides, 4-phenylthiosemicarbazide and 4-(3-nitrophenyl)-3-
thiosemicarbazide. Two methods of synthesis employed HBTU as a coupling agent as a 
means of amide bond formation between the monocarboxylic acid and the amine of the 
thiosemicarbazide, but these attempts were faced with challenges with regards to 
reproducibility, or, in the case of the nitrothiosemicarbazide, apparent difficulties with 
selectivity of the HBTU in the presence of strong electron-withdrawing groups on the 
aromatic ring. In order to bypass the need for a coupling agent, an additional procedure 
was carried out which involved the conversion of ferrocene monocarboxylic acid into 
ferrocene carbonyl chloride through treatment with oxalyl chloride. The choice to create 
a carbonyl chloride yielded very positive results and, given enough time to continue 
purifying the final product, might actually be a more effective and simpler means of 
attaching a thiosemicarbazide onto the ferrocene. 
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Given additional time to complete this project, there are a number of additional 
steps which could be taken. Because of the success achieved using a carbonyl chloride 
intermediate, the products of these reactions could be further purified to achieve, 
potentially, any number of thiosemicarbazide structures. Once a method for the 
purification of these new structures could be identified, the structures could be reacted 
with mercury in a similar prep of the first oxadiazole, in order to see whether or not 
intramolecular cyclization will still occur in the presence of various other R groups on the 
thiosemicarbazide. If it is found that oxadiazole were, in fact, formed during this step, a 
determination of their LogD values, metabolic stability using a microsomal stability 
assay, and other in vitro tests could be used to further assess whether or not these new 
molecules possess any type of medicinal properties. 
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